These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32632929)

  • 1. Management and tolerability of glecaprevir-pibrentasvir pharmacotherapy in hepatitis C viremic heart and lung transplant recipients.
    Lewis TC; Gidea C; Reyentovich A; Angel L; Lesko M; Pavone J; Sureau K; Smith DE; Kon Z; Moazami N
    Clin Transplant; 2020 Oct; 34(10):e14030. PubMed ID: 32632929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
    Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
    J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors.
    Reyentovich A; Gidea CG; Smith D; Lonze B; Kon Z; Fargnoli A; Pavone J; Rao S; Saraon T; Lewis T; Qian Y; Jacobson I; Moazami N
    Clin Transplant; 2020 Sep; 34(9):e13989. PubMed ID: 32441413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients.
    Nnani DU; Campbell A; Ajaimy M; Saeed O; Patel SR; Ahmed S; Graham JA; Jorde UP
    Transpl Infect Dis; 2021 Oct; 23(5):e13716. PubMed ID: 34407270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful nasoenteric administration of glecaprevir/pibrentasvir for donor-derived hepatitis C in two young adult heart transplant recipients at a pediatric transplant center.
    Kushner LE; Puckett L; Lee J; Joerger T; Chen SF; Profita E
    Pediatr Transplant; 2022 Nov; 26(7):e14360. PubMed ID: 35854405
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
    Aragri M; Milana M; Di Maio VC; Lenci I; Carioti L; Perno CF; Svicher V; Angelico M; Ceccherini-Silberstein F
    Clin Microbiol Infect; 2020 Sep; 26(9):1266-1268. PubMed ID: 32240711
    [No Abstract]   [Full Text] [Related]  

  • 7. High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use: Some issues.
    Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML
    J Infect; 2022 Oct; 85(4):e94-e95. PubMed ID: 35810942
    [No Abstract]   [Full Text] [Related]  

  • 8. Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia.
    Chen HW; Hsieh CB; Hsieh TY; Lin JC
    J Formos Med Assoc; 2021 Jun; 120(6):1408-1409. PubMed ID: 33272749
    [No Abstract]   [Full Text] [Related]  

  • 9. [A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
    Wang CY; Liu J; Wen J; Ma HX; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2021 Dec; 29(12):1194-1195. PubMed ID: 35045636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glecaprevir/Pibrentasvir and Renal Dysfunction in Deceased Donor Renal Transplantation: A Case Report.
    Kaba A; Yamanaga S; Hidaka Y; Toyoda M; Kashima M; Takekuma Y; Inadome A; Yokomizo H; Miyata A
    Transplant Proc; 2022 Mar; 54(2):549-551. PubMed ID: 35120765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C and beta-thalassemia major in children: experience with glecaprevir/pibrentasvir.
    Quintero García D; Sebastián Cuevas FJ; Crehuá Gaudiza E
    Rev Esp Enferm Dig; 2021 Feb; 113(2):150-151. PubMed ID: 33207896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to "Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia".
    Yu ML; Kao JH
    J Formos Med Assoc; 2021 Jun; 120(6):1410-1411. PubMed ID: 33422401
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
    Lampertico P; Mauss S; Persico M; Barclay ST; Marx S; Lohmann K; Bondin M; Zhang Z; Marra F; Belperio PS; Wedemeyer H; Flamm S
    Adv Ther; 2020 Sep; 37(9):4033-4042. PubMed ID: 32754824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
    Umemura M; Suda G; Tsukamoto S; Ebata K; Takahash S; Sasaki T; Nakajima S; Hirata K; Ozasa M; Takano M; Katagiri M; Sakamoto N
    BMC Infect Dis; 2021 Apr; 21(1):389. PubMed ID: 33906643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.
    Bethea ED; Gaj K; Gustafson JL; Axtell A; Lebeis T; Schoenike M; Turvey K; Coglianese E; Thomas S; Newton-Cheh C; Ibrahim N; Carlson W; Ho JE; Shah R; Nayor M; Gift T; Shao S; Dugal A; Markmann J; Elias N; Yeh H; Andersson K; Pratt D; Bhan I; Safa K; Fishman J; Kotton C; Myoung P; Villavicencio MA; D'Alessandro D; Chung RT; Lewis GD
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):771-780. PubMed ID: 31353243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
    Turnes J; Rincón D; Calleja JL; Delgado MB; Rosales JM; Andrade RJ; Manzano ML; Salmerón FJ; López MA; Calvo M; Gómez J; Molina E; Frias YN; Gálvez-Fernández RM; Vallejo-Senra N; París S; Santos de Lamadrid R; Olveira A
    Gastroenterol Hepatol; 2022 May; 45(5):342-349. PubMed ID: 34129903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
    Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
    J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
    Yao BB; Fredrick LM; Schnell G; Kowdley KV; Kwo PY; Poordad F; Nguyen K; Lee SS; George C; Wong F; Gane E; Abergel A; Spearman CW; Nguyen T; Hung Le M; Pham TT; Mensa F; Asselah T
    Liver Int; 2020 Oct; 40(10):2385-2393. PubMed ID: 32445613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.
    Klinker H; Naumann U; Rössle M; Berg T; Bondin M; Lohmann K; Koenig B; Zeuzem S; Cornberg M
    Liver Int; 2021 Jul; 41(7):1518-1522. PubMed ID: 33966349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.
    Wedemeyer H; Erren P; Naumann U; Rieke A; Stoehr A; Zimmermann T; Lohmann K; König B; Mauss S
    Liver Int; 2021 May; 41(5):949-955. PubMed ID: 33592123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.